Trial Profile
Evaluation of the effect and safety of RituxCIM (biosimilar Rituximab) in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 07 Jan 2014 New trial record